PETALING JAYA: Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare( CHC) segment, while sales to the government sector is also expected to increase in 2024.In a report, TA Research said it remains optimistic on Duopharma’s growth prospects with catalysts coming from these two factors.“ To recap, nine-month 2023( 9M23) net profit dipped 16.6% to RM44. 1mil due to weaker CHC sales, the upward adjustment in the electricity tariff, a weak ringgit and higher finance cost.“ Fo
综合
星报-商业
2024-01-26 00:00:00.0